Gyre Therapeutics (GYRE) Equity Average (2011 - 2026)
Gyre Therapeutics (GYRE) reported Equity Average of $121.5 million for Q1 2026, up 19.89% year-over-year from $101.4 million in Q1 2025, and up 16.86% on a QoQ basis from $104.0 million in Q4 2025.
Gyre Therapeutics (GYRE) has 16 years of Equity Average data on file, last reported at $121.5 million in Q1 2026.
- Quarterly Equity Average rose 19.89% year-over-year to $121.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.5 million (up 19.89% YoY) and the FY2025 annual result came in at $102.2 million, up 81.96% from the prior year.
- Equity Average climbed to $121.5 million in Q1 2026 per GYRE's latest filing, from $104.0 million in the prior quarter.
- Across five years, Equity Average topped out at $121.5 million in Q1 2026 and bottomed at $43.3 million in Q1 2022.
- The 5-year median for Equity Average is $81.4 million (2023), against an average of $81.2 million.
- The widest annual swing landed in 2022, when Equity Average tumbled 51.96%; it then surged 98.33% in 2024.
- Tracing GYRE's Equity Average over 5 years: stood at $50.8 million in 2022, then fell by 2.29% to $49.6 million in 2023, then soared by 98.33% to $98.4 million in 2024, then rose by 5.63% to $104.0 million in 2025, then rose by 16.86% to $121.5 million in 2026.
- Per Business Quant, the three latest GYRE Equity Average figures stand at $121.5 million (Q1 2026), $104.0 million (Q4 2025), and $115.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | 121.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 121.51 Mn |
| Dec 31, 2025 | 103.98 Mn |
| Sep 30, 2025 | 115.68 Mn |
| Jun 30, 2025 | 116.87 Mn |
| Mar 31, 2025 | 101.35 Mn |
| Dec 31, 2024 | 98.44 Mn |
| Sep 30, 2024 | 95.91 Mn |
| Jun 30, 2024 | 91.06 Mn |
| Mar 31, 2024 | 51.36 Mn |
| Dec 31, 2023 | 49.63 Mn |
| Sep 30, 2023 | 81.39 Mn |
| Jun 30, 2023 | 77.40 Mn |
| Mar 31, 2023 | 74.77 Mn |
| Dec 31, 2022 | 50.80 Mn |
| Sep 30, 2022 | 54.22 Mn |
| Jun 30, 2022 | 53.07 Mn |
| Mar 31, 2022 | 43.27 Mn |
| Dec 31, 2021 | 60.10 Mn |
| Sep 30, 2021 | 72.95 Mn |
| Jun 30, 2021 | 94.63 Mn |
| Mar 31, 2021 | 90.08 Mn |
| Dec 31, 2020 | 85.06 Mn |
| Sep 30, 2020 | 101.51 Mn |
| Jun 30, 2020 | 103.24 Mn |
| Mar 31, 2020 | 82.93 Mn |
| Dec 31, 2019 | 74.80 Mn |
| Sep 30, 2019 | 87.19 Mn |
| Jun 30, 2019 | 99.46 Mn |
| Mar 31, 2019 | 112.88 Mn |
| Dec 31, 2018 | 124.95 Mn |
| Sep 30, 2018 | 133.46 Mn |
| Jun 30, 2018 | 139.91 Mn |
| Mar 31, 2018 | 86.81 Mn |
| Dec 31, 2017 | 27.83 Mn |
| Sep 30, 2017 | 27.61 Mn |
| Jun 30, 2017 | 22.09 Mn |
| Mar 31, 2017 | 14.95 Mn |
| Dec 31, 2016 | 17.84 Mn |
| Sep 30, 2016 | 21.54 Mn |
| Jun 30, 2016 | 25.74 Mn |
| Mar 31, 2016 | 29.71 Mn |
| Dec 31, 2015 | 33.82 Mn |
| Sep 30, 2015 | 67.87 Mn |
| Jun 30, 2015 | 101.38 Mn |
| Mar 31, 2015 | -3.06 Mn |
| Dec 31, 2014 | 1.78 Mn |
| Sep 30, 2014 | 114.96 Mn |
| Jun 30, 2014 | 120.56 Mn |
| Mar 31, 2014 | 10.55 Mn |
| Dec 31, 2013 | 21.86 Mn |
| Sep 30, 2013 | 152.46 Mn |
| Jun 30, 2013 | 163.82 Mn |
| Mar 31, 2013 | 38.06 Mn |
| Dec 31, 2012 | 48.62 Mn |
| Sep 30, 2012 | 193.47 Mn |
| Jun 30, 2012 | 187.53 Mn |
| Mar 31, 2012 | 176.50 Mn |
| Dec 31, 2011 | 178.15 Mn |
| Sep 30, 2011 | 185.56 Mn |